USA – Fujifilm has acquired Inspirata’s Dynamyx digital pathology technology to strengthen its efforts in delivering high-quality and affordable diagnostic imaging services.
In December 2022, Fujifilm and Florida-based company Inspirata signed an asset purchase agreement for Fujifilm to acquire Inspirata’s digital pathology technology along with its employees and customers.
Following the completion of the acquisition, Inspirata’s Dynamyx digital platform and the team responsible for building its advanced digital pathology workflow are now part of FUJIFILM Healthcare Americas Corporation.
Dynamyx, an open, vendor-agnostic, end-to-end digital pathology solution, has been integrated into Fujifilm’s Synapse Enterprise Imaging portfolio.
Its software capabilities include using whole slide images from multiple scanning vendors to create an easier path for more pathology labs to digitize and realize the benefits of faster patient results, centralized imaging records, and enterprise access to images for all clinicians.
The successful acquisition will support Fujifilm in bridging a technological gap between pathology, radiology, and oncology to facilitate a more collaborative approach to care delivery across the enterprise.
In addition, Fujifilm has introduced a pathology division of its Medical Informatics business to deliver on the significant demand and market growth potential of the digital pathology market.
“We’re proud and grateful to begin 2023 welcoming Inspirata’s digital pathology team to our organization,” Bill Lacy, Senior Vice President, Medical Informatics, FUJIFILM Healthcare Americas Corporation, said in a statement.
Fujifilm’s innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery.
With the new digital pathology division expanding, Fujifilm has expanded its award-winning enterprise imaging portfolio that will help streamline care delivery for oncology patients and provider teams.
The pathology business will also enable the digitization and integration of pathology images and data into the healthcare organization’s electronic health record system.
The company announced that it has appointed business leader Dr. Mark Lloyd to head its new pathology division, noting that Dr. Mark is the Head Scientist of the Dynamyx product bringing over 20 years of pathology experience to the organization.
Upon being notified of his additional role, Dr. Mark Lloyd, Vice President of Pathology at FUJIFILM Healthcare Americas Corporation, said: “Transforming and improving the diagnostic experience for patients and care teams has been the force driving my life’s work.”
He underscored that the partnership allows the digital pathology business to flourish with a partner with the breadth, depth, and resources required to take the Dynamyx platform to the next stage of its growth and international expansion.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
